Skip to content
Building a Drug Empire on Undervalued Assets episode artwork

May 9, 2019 35 min

Building a Drug Empire on Undervalued Assets

from The Bio Report Hosted by Levine Media Group

Roivant Sciences doesn’t fit easily into conceptions of drug companies, venture capital firms, or accelerators. It is building highly-focused drug development companies around promising undervalued assets it licenses. In five years’ time, it’s raised more than $3 billion, amassed a broad pipeline of more than 35 therapies, and has more than 800 employees. We spoke to Eric Venker, chief operating officer of Roivant, about the company’s business model, how it leverages its resources, and how it may be changing the industry’s approach to drug development.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Building a Drug Empire on Undervalued Assets

0:00 35:41

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 35 minutes long.

When was this The Bio Report episode published?

This episode was published on May 9, 2019.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.